Psoriatic Arthritis
7 competing products in clinical development for Psoriatic Arthritis.
Pipeline by Phase
Phase 22
Phase 2/31
Phase 33
Approved1
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ixekizumab + Tirzepatide | Eli Lilly | Phase 3 | Active | 44 |
| TILD sub-cutaneous (SC) injection | Sun Pharmaceutical | Phase 3 | Active | 44 |
| Ixekizumab + Adalimumab | Eli Lilly | Approved | Completed | 43 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | Completed | 40 |
| SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg) | Sun Pharmaceutical | Phase 2/3 | Completed | 38 |
| Alefacept + Methotrexate + Placebo | Astellas Pharma | Phase 2 | Completed | 35 |
| Dose A VTX958 + Dose B VTX958 + Placebo | Ventyx Biosciences | Phase 2 | Terminated | 21 |